Milestone for Skyepharma as Flutiform debuts in Spain; and as Abriff in Italy

1 December 2014

UK oral and inhalation drug specialist Skyepharma (LSE: SKP) says that, following regulatory approval and agreement on pricing reimbursement, Flutiform has now been launched in Spain for the treatment of bronchial asthma.

The drug has also been launched in Italy as Abriff under a co-marketing agreement. Flutiform and Abriff combine the fast-acting long-acting beta agonist (LABA) formoterol with the most widely prescribed inhaled corticosteroid (ICS) fluticasone. SkyePharma shares gained 2.6% to365.74 pence in morning trading.

Following the launch in Spain, a milestone of 2.0 million euros ($2.5 million at current exchange rates) is now payable to Skyepharma by its licensee, privately-held Swiss firm Mundipharma International, together with royalties on net sales and revenues on product supply.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK